Iambic Therapeutics, Inc. (IAM)

NASDAQ: IAM · Real-Time Price · USD

15.39

+0.61 (4.09%)

At close: Nov 11, 2026, 4:00 PM EST

15.22

-0.16 (-1.06%)

Pre-market: Nov 12, 2026, 4:57 AM EST

Iambic Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	18.25	9.43	1.19
Revenue Growth	-	689.45%	-
Gross Profit	-83.49	-68.1	-44.5
Operating Income	-100.19	-82.35	-53.88
Net Income	-94.25	-77.3	-47.88
Earnings Per Share	-4.27	-3.57	-2.23
EPS Growth	-	-	-

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Investments	207.88	180.54	141.58
Total Debt	5.23	5.65	6.5
Net Cash (Debt)	202.65	174.89	135.08
Net Cash Growth	-	29.47%	-
Net Cash Per Share	9.18	8.09	6.31

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Cash Flow	-65.73	-58.82	-33.56
Capital Expenditures	-2.44	-1.28	-0.71
Free Cash Flow	-68.17	-60.1	-34.27
Free Cash Flow Growth	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Margin	-548.93%	-873.65%	-4512.31%
Pretax Margin	-516.13%	-819.54%	-4006.95%
Profit Margin	-516.39%	-820.02%	-4009.80%
FCF Margin	-373.50%	-637.63%	-2869.93%